Balenine alleviates neurodegeneration and inflammation in a mouse model of Parkinson's disease

Carnosine, an imidazole dipeptide, has potential for treating neurodegenerative diseases, including Parkinson's disease. However, carnosine-degrading enzymes limit its bioavailability. In this study, we established a mouse model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (MPTP)-induced Parkinson's disease and intranasally administered balenine, a carnosine analog featuring a methylated imidazole that is resistant to degradation enzymes, to target the brain via the olfactory epithelium. MPTP + balenine-treated mice demonstrated improved recognition scores in the object location test. They also exhibited a significantly increased tyrosine hydroxylase-positive cells and reduced expression of glial fibrillary acidic protein, an inflammatory marker, indicating that balenine mitigated neurodegenerative damage and inflammation in mice with MPTP-induced Parkinson's disease. Proteomic analysis revealed that activation of the KEAP1-NFE2L2 pathway, neddylation, and GSK3B and BTRC:CUL1-mediated degradation of NFE2L2. Collectively, these results highlight the efficacy of intranasal drops of balenine in Parkinson's disease and their potential to improve neurodegenerative disease prognosis. • Balenine was intransally administered to MPTP-induced Parkinson's disease mice. • MPTP + balenine-treated mice demonstrated improved recognition scores. • Balenine mitigated neurodegenerative damage and inflammation. • Intranasal balenine drops is an effective Parkinson's disease treatment.